Main image Main image

Cend Therapeutics in the News

August 13, 2018

DrugCendR Inc., a biopharmaceutical company dedicated to developing next generation cancer therapies designed to overcome the barriers of drug delivery in solid tumors, announced today the treatment of the first patient in a Phase 1 clinical trial evaluating its lead compound CEND-1 (scientifically known as iRGD), in patients with metastatic pancreatic adenocarcinoma (CEND1-001, Clinical trial reference NCT03517176).

 

“Treating the first patient is an exciting milestone for our technology platform and for the company.” said Erkki Ruoslahti, President and CEO of DrugCendR Inc. “We chose to conduct the first study in pancreatic cancer, a cancer that is in desperate need of more effective therapies and shown to respond to CEND-1. Studies in preclinical models conducted all over the world also show that CEND-1 has wider potential; it enhances the therapy of many types of cancers by many types of drugs. We hope to make that potential a reality in the treatment of human cancer.”

 

Chief Operating Officer, Harri Jarvelainen continues, “We initiated our IND-enabling program a year ago so it is a great achievement to start dosing in this multi-site trial already now. Data from more than 100 publications have consistently demonstrated that CEND-1 is effective in the treatment of various types of solid tumors – but importantly, it is also a safe and well-tolerated compound, thanks to its tumor specific mechanism of action. As the extent of preclinical validation is almost unprecedented, we have a high confidence in the clinical translation of our therapy and hope that it will be soon available to patients with this and other cancers with high unmet medical need.”

 

Click here to read the full news release.

August 10, 2018
March 10, 2018

Contact us for more information.